What is the standard of care for locally advanced Sarcoma according to NCCN guidelines

Standard of Care for Locally Advanced Sarcoma (NCCN Guidelines)

The treatment approach for locally advanced sarcoma depends on whether the tumor can be surgically removed while preserving acceptable function. Let me break down what the NCCN Guidelines recommend:

Key Treatment Principles

According to the NCCN Guidelines for Soft Tissue Sarcoma (Version 1.2025), locally advanced sarcomas are typically classified as Stage II or III tumors. The standard of care involves a multidisciplinary approach combining surgery, radiation therapy, and sometimes systemic chemotherapy.

Treatment Options Based on Resectability

If the tumor is RESECTABLE with acceptable functional outcomes:

• Surgery first with oncologically appropriate margins (wide surgical removal with negative margins)
• Adjuvant radiation therapy (RT) after surgery to reduce local recurrence risk
• Consider adjuvant systemic therapy (chemotherapy) in selected cases

If the tumor is RESECTABLE but with UNACCEPTABLE functional outcomes:

The NCCN Guidelines outline several options:

• Radiation therapy alone (if not previously given)
• Systemic therapy (chemotherapy) combined with radiation
• Systemic therapy alone
• Isolated limb perfusion/infusion (a specialized technique available at experienced centers)
• Amputation or radical resection (in select cases)

If the tumor is UNRESECTABLE:

• Definitive radiation therapy (if not previously given)
• Systemic therapy (chemotherapy)
• Palliative surgery (to relieve symptoms)
• Observation (if asymptomatic)
• Best supportive care

The Role of Radiation Therapy

Radiation is a cornerstone of locally advanced sarcoma treatment. According to NCCN Guidelines, it's typically given:

• Neoadjuvant (before surgery) to shrink the tumor
• Adjuvant (after surgery) to eliminate microscopic disease and reduce recurrence risk

The Role of Chemotherapy

The evidence for chemotherapy in locally advanced sarcoma is nuanced:

• Chemotherapy may be considered as part of neoadjuvant or adjuvant treatment
• Benefits appear most significant in high-grade tumors and specific histologic subtypes (like leiomyosarcoma)
• The NCCN Guidelines note that chemotherapy decisions should be individualized based on tumor characteristics

Important Considerations

Multidisciplinary Team Approach: The NCCN Guidelines emphasize that treatment planning should involve surgical oncologists, radiation oncologists, and medical oncologists working together to determine the best approach for YOUR specific situation.

Functional Preservation: A major goal is preserving limb function and quality of life while achieving local control (preventing the cancer from growing back locally).

Histology Matters: Different sarcoma subtypes may respond differently to treatment, so your specific sarcoma type influences recommendations.

Questions to Ask Your Oncology Team

1. What is the specific histologic type and grade of my sarcoma? (This determines treatment sensitivity)
2. Is my tumor considered resectable, and if so, what would be the functional impact of surgery?
3. What is the recommended sequence of treatment—surgery first, or neoadjuvant therapy first?
4. Will I need radiation therapy, and if so, when and for how long?
5. Is chemotherapy recommended for my specific sarcoma type, and what are the potential benefits and side effects?
6. What is your experience with treating sarcomas, and do you recommend a second opinion at a sarcoma specialty center?

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.

Sources: NCCN Guidelines for Soft Tissue Sarcoma (Version 1.2025)